Computational screening identified fungal secondary metabolites—including Phellibaumin A and Daldinone B—that strongly bind to DNA polymerase beta, a key liver cancer enzyme. These compounds showed favorable docking scores, low predicted toxicity, and good drug-like properties. Phellibaumin A stood out as the top candidate, suggesting medicinal mushrooms could yield future therapies against liver cancer.